368 related articles for article (PubMed ID: 26428020)
1. FDA drug labeling for pregnancy and lactation drug safety monitoring systems.
Greene MF
Semin Perinatol; 2015 Nov; 39(7):520-3. PubMed ID: 26428020
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of medications use in pregnancy.
Ayad M; Costantine MM
Semin Perinatol; 2015 Nov; 39(7):508-11. PubMed ID: 26358804
[TBL] [Abstract][Full Text] [Related]
3. US lawmakers tackle safety reforms at the FDA.
Zwillich T
Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
[No Abstract] [Full Text] [Related]
4. The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule.
Brucker MC; King TL
J Midwifery Womens Health; 2017 May; 62(3):308-316. PubMed ID: 28556499
[TBL] [Abstract][Full Text] [Related]
5. Medication use in pregnancy and the pregnancy and lactation labeling rule.
Sahin L; Nallani SC; Tassinari MS
Clin Pharmacol Ther; 2016 Jul; 100(1):23-5. PubMed ID: 27082701
[TBL] [Abstract][Full Text] [Related]
6. Bolstering the FDA's drug-safety authority.
Schultz WB
N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
[No Abstract] [Full Text] [Related]
7. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2014 Dec; 79(233):72063-103. PubMed ID: 25509060
[TBL] [Abstract][Full Text] [Related]
8. The Importance of Clinical Research in Pregnant Women to Inform Prescription Drug Labeling.
Dinatale M; Roca C; Sahin L; Johnson T; Mulugeta LY; Fletcher EP; Yao L
J Clin Pharmacol; 2020 Dec; 60 Suppl 2():S18-S25. PubMed ID: 33274508
[TBL] [Abstract][Full Text] [Related]
9. Changes to Pregnancy and Lactation Risk Labeling for Prescription Drugs.
Fantasia HC; Harris AL
Nurs Womens Health; 2015; 19(3):266-70. PubMed ID: 26058910
[TBL] [Abstract][Full Text] [Related]
10. Regulatory experts debate FDA's authority.
Young D
Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
[No Abstract] [Full Text] [Related]
11. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
Gass A; Wilson J
Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
[No Abstract] [Full Text] [Related]
12. FDA's proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use.
Feibus KB
J Med Toxicol; 2008 Dec; 4(4):284-8. PubMed ID: 19031382
[TBL] [Abstract][Full Text] [Related]
13. Assessing congenital malformation risk from medications used in pregnancy: The contribution of NBDPS in pregnancy labeling of prescription drug products.
Tassinari MS; Sahin L; Yao LP
Birth Defects Res A Clin Mol Teratol; 2015 Aug; 103(8):718-20. PubMed ID: 26223007
[TBL] [Abstract][Full Text] [Related]
14. PLIVA v. Mensing: generic consumers' unfortunate hand.
Lee SB
Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
[No Abstract] [Full Text] [Related]
15. The US FDA pregnancy lactation and labeling rule - Implications for maternal immunization.
Gruber MF
Vaccine; 2015 Nov; 33(47):6499-500. PubMed ID: 26256527
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Pregnancy and Lactation Labeling Rule (PLLR) on Practicing Dermatologists.
Beroukhim K; Abrouk M; Farahnik B
Dermatol Online J; 2015 Nov; 21(11):. PubMed ID: 26632938
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceuticals and medical devices: FDA oversight.
Berry MD
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
[No Abstract] [Full Text] [Related]
19. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.
O'Reilly J; Dalal A
Ann Health Law; 2003; 12(2):295-324, table of contents. PubMed ID: 12856461
[TBL] [Abstract][Full Text] [Related]
20. A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.
Allan MC
J Pharm Technol; 1992; 8(4):162-7. PubMed ID: 10121011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
